Annual CFO
-$132.26 M
+$115.94 M+46.71%
December 31, 2023
Summary
- As of February 23, 2025, FATE annual cash flow from operations is -$132.26 million, with the most recent change of +$115.94 million (+46.71%) on December 31, 2023.
- During the last 3 years, FATE annual CFO has fallen by -$93.03 million (-237.16%).
- FATE annual CFO is now -989.03% below its all-time high of -$12.14 million, reached on December 31, 2011.
Performance
FATE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$29.42 M
+$2.89 M+8.94%
September 30, 2024
Summary
- As of February 23, 2025, FATE quarterly cash flow from operations is -$29.42 million, with the most recent change of +$2.89 million (+8.94%) on September 30, 2024.
- Over the past year, FATE quarterly CFO has increased by +$8.85 million (+23.13%).
- FATE quarterly CFO is now -175.74% below its all-time high of $38.84 million, reached on June 30, 2020.
Performance
FATE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$131.71 M
+$8.85 M+6.30%
September 30, 2024
Summary
- As of February 23, 2025, FATE TTM cash flow from operations is -$131.71 million, with the most recent change of +$8.85 million (+6.30%) on September 30, 2024.
- Over the past year, FATE TTM CFO has increased by +$39.30 million (+22.98%).
- FATE TTM CFO is now -3248.89% below its all-time high of -$3.93 million, reached on March 31, 2013.
Performance
FATE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
FATE Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +46.7% | +23.1% | +23.0% |
| 3 y3 years | -237.2% | -1.9% | +38.0% |
| 5 y5 years | -242.2% | -10.3% | -42.6% |
FATE Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +46.7% | -3.3% | +61.0% | at high | +46.9% |
| 5 y | 5-year | -237.2% | +46.7% | -175.7% | +61.0% | -296.7% | +46.9% |
| alltime | all time | -989.0% | +46.7% | -175.7% | +61.0% | -3248.9% | +46.9% |
Fate Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$29.42 M(-8.9%) | -$131.71 M(-6.3%) |
| Jun 2024 | - | -$32.31 M(-3.1%) | -$140.57 M(+2.8%) |
| Mar 2024 | - | -$33.35 M(-9.0%) | -$136.75 M(+3.4%) |
| Dec 2023 | -$132.26 M(-46.7%) | -$36.64 M(-4.3%) | -$132.26 M(-22.7%) |
| Sep 2023 | - | -$38.27 M(+34.3%) | -$171.01 M(-8.9%) |
| Jun 2023 | - | -$28.49 M(-1.3%) | -$187.79 M(-11.6%) |
| Mar 2023 | - | -$28.86 M(-61.7%) | -$212.46 M(-14.4%) |
| Dec 2022 | -$248.21 M(+52.4%) | -$75.39 M(+37.0%) | -$248.21 M(+2.1%) |
| Sep 2022 | - | -$55.05 M(+3.6%) | -$243.11 M(+9.8%) |
| Jun 2022 | - | -$53.16 M(-17.7%) | -$221.44 M(+10.5%) |
| Mar 2022 | - | -$64.61 M(-8.1%) | -$200.39 M(+23.0%) |
| Dec 2021 | -$162.87 M(+315.2%) | -$70.29 M(+110.6%) | -$162.87 M(+43.8%) |
| Sep 2021 | - | -$33.38 M(+4.0%) | -$113.24 M(+2.4%) |
| Jun 2021 | - | -$32.11 M(+18.5%) | -$110.60 M(+178.9%) |
| Mar 2021 | - | -$27.10 M(+31.1%) | -$39.65 M(+1.1%) |
| Dec 2020 | -$39.23 M(-52.8%) | -$20.66 M(-32.8%) | -$39.23 M(-11.0%) |
| Sep 2020 | - | -$30.73 M(-179.1%) | -$44.10 M(+32.8%) |
| Jun 2020 | - | $38.84 M(-245.6%) | -$33.20 M(-64.0%) |
| Mar 2020 | - | -$26.67 M(+4.5%) | -$92.36 M(+11.0%) |
| Dec 2019 | -$83.17 M(+115.2%) | -$25.54 M(+28.7%) | -$83.17 M(+21.1%) |
| Sep 2019 | - | -$19.84 M(-2.3%) | -$68.66 M(+31.1%) |
| Jun 2019 | - | -$20.31 M(+16.1%) | -$52.38 M(+20.2%) |
| Mar 2019 | - | -$17.49 M(+58.7%) | -$43.59 M(+12.8%) |
| Dec 2018 | -$38.65 M | -$11.02 M(+209.9%) | -$38.65 M(+0.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$3.56 M(-69.1%) | -$38.35 M(-13.9%) |
| Jun 2018 | - | -$11.52 M(-8.2%) | -$44.56 M(+6.3%) |
| Mar 2018 | - | -$12.55 M(+17.1%) | -$41.91 M(+13.8%) |
| Dec 2017 | -$36.82 M(+23.5%) | -$10.72 M(+9.7%) | -$36.82 M(+9.4%) |
| Sep 2017 | - | -$9.77 M(+10.1%) | -$33.65 M(+7.2%) |
| Jun 2017 | - | -$8.87 M(+19.0%) | -$31.39 M(+4.6%) |
| Mar 2017 | - | -$7.46 M(-1.3%) | -$30.03 M(+0.7%) |
| Dec 2016 | -$29.82 M(+62.1%) | -$7.55 M(+0.5%) | -$29.82 M(+2.0%) |
| Sep 2016 | - | -$7.52 M(+0.2%) | -$29.24 M(+1.3%) |
| Jun 2016 | - | -$7.50 M(+3.5%) | -$28.86 M(+49.7%) |
| Mar 2016 | - | -$7.25 M(+4.0%) | -$19.27 M(+4.8%) |
| Dec 2015 | -$18.40 M(-17.9%) | -$6.97 M(-2.3%) | -$18.40 M(+4.6%) |
| Sep 2015 | - | -$7.13 M(-443.0%) | -$17.58 M(+10.1%) |
| Jun 2015 | - | $2.08 M(-132.6%) | -$15.97 M(-32.2%) |
| Mar 2015 | - | -$6.38 M(+3.6%) | -$23.54 M(+5.0%) |
| Dec 2014 | -$22.42 M(+45.8%) | -$6.15 M(+11.5%) | -$22.42 M(+7.6%) |
| Sep 2014 | - | -$5.52 M(+0.6%) | -$20.84 M(+10.9%) |
| Jun 2014 | - | -$5.49 M(+4.5%) | -$18.79 M(+12.6%) |
| Mar 2014 | - | -$5.25 M(+14.8%) | -$16.70 M(+8.6%) |
| Dec 2013 | -$15.37 M(+15.8%) | -$4.58 M(+31.9%) | -$15.37 M(+42.4%) |
| Sep 2013 | - | -$3.47 M(+2.4%) | -$10.79 M(+47.4%) |
| Jun 2013 | - | -$3.39 M(-13.8%) | -$7.32 M(+86.2%) |
| Mar 2013 | - | -$3.93 M | -$3.93 M |
| Dec 2012 | -$13.27 M(+9.3%) | - | - |
| Dec 2011 | -$12.14 M | - | - |
FAQ
- What is Fate Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Fate Therapeutics?
- What is Fate Therapeutics annual CFO year-on-year change?
- What is Fate Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Fate Therapeutics?
- What is Fate Therapeutics quarterly CFO year-on-year change?
- What is Fate Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Fate Therapeutics?
- What is Fate Therapeutics TTM CFO year-on-year change?
What is Fate Therapeutics annual cash flow from operations?
The current annual CFO of FATE is -$132.26 M
What is the all time high annual CFO for Fate Therapeutics?
Fate Therapeutics all-time high annual cash flow from operations is -$12.14 M
What is Fate Therapeutics annual CFO year-on-year change?
Over the past year, FATE annual cash flow from operations has changed by +$115.94 M (+46.71%)
What is Fate Therapeutics quarterly cash flow from operations?
The current quarterly CFO of FATE is -$29.42 M
What is the all time high quarterly CFO for Fate Therapeutics?
Fate Therapeutics all-time high quarterly cash flow from operations is $38.84 M
What is Fate Therapeutics quarterly CFO year-on-year change?
Over the past year, FATE quarterly cash flow from operations has changed by +$8.85 M (+23.13%)
What is Fate Therapeutics TTM cash flow from operations?
The current TTM CFO of FATE is -$131.71 M
What is the all time high TTM CFO for Fate Therapeutics?
Fate Therapeutics all-time high TTM cash flow from operations is -$3.93 M
What is Fate Therapeutics TTM CFO year-on-year change?
Over the past year, FATE TTM cash flow from operations has changed by +$39.30 M (+22.98%)